Does romosozumab improve bone strength in postmenopausal women with osteoporosis?
Romosozumab is a medication that works by inhibiting sclerostin, a protein that slows bone formation. For postmenopausal women with osteoporosis, the key question is whether this drug actually makes bones stronger, not just denser. Clinical studies using advanced imaging techniques like quantitative computed tomography (QCT) and finite element analysis (FEA) show that romosozumab improves multiple measures of bone strength, including shear strength at the spine and overall vertebral strength. These improvements translate to a lower risk of fractures.
What the research says
A substudy of two randomized trials used biomechanical computed tomography (BCT) to measure shear bone strength around pedicle screws in the spine. After 12 months, women taking romosozumab showed significant improvements in shear bone strength compared to those on placebo or teriparatide 1. Similarly, the ARCH trial used QCT and FEA to assess lumbar spine bone strength. Romosozumab for 12 months led to greater gains in volumetric bone mineral density (vBMD), bone mineral content, and estimated bone strength compared to alendronate 9. Another analysis from ARCH found that romosozumab improved trabecular bone score (TBS), an indirect measure of bone microarchitecture, more than alendronate. These gains were maintained even after switching to alendronate 11. A separate study showed that transitioning from denosumab to romosozumab improved lumbar spine BMD and TBS more than continuing denosumab alone 10. A narrative review notes that romosozumab combines robust anti-fracture efficacy with unresolved cardiovascular safety questions, so the bone strength benefits must be weighed against potential risks 6.
What to ask your doctor
- Based on my bone density and fracture risk, is romosozumab a good option for improving my bone strength?
- What do the improvements in bone strength seen in studies mean for my personal risk of spine or hip fractures?
- How does romosozumab compare with other osteoporosis medications like alendronate or denosumab in terms of bone strength and safety?
- What are the known cardiovascular risks associated with romosozumab, and how do they apply to my health history?
- If I start romosozumab, how long would I need to take it, and what would the next treatment step be?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.